Compare Gilead Sciences, Inc. (GILD) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Levi Strauss & Co. — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Levi Strauss & Co. trades at $19.01 (market cap $7.51B). The key difference: Gilead Sciences, Inc. is far larger — about 24.2× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Levi Strauss & Co. for 70 Days on average.
| GILD | LEVI | |
|---|---|---|
Market Cap | $182.09B | $7.51B |
Volume | 4,960,247 | 17,462,954 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $25.53 |
52-Week Low | $116.74 | $17.92 |
Typical Hold Time | 111 Days | 70 Days |
Enterprise Value | $205.15B | $9.06B |
Dividend Yield | 2.23% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Levi Strauss (LEVI) trades at $19.05, down 7.21% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.84, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights a '90s fashion revival benefiting the brand and the appointment of a new CFO effective November 2026. Cash flow trends have improved, with net cash flow turning positive in 2025 after prior volatility.
The outlook is positive given analyst consensus of a $27.80 price target and 79% buy ratings, though near-term price weakness and competitive pressures in apparel present risks. Earnings growth and direct-to-consumer expansion are key catalysts, but investors face execution risks and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
